ReviewEye (London, England)2019
Acute primary angle closure-treatment strategies, evidences and economical considerations.
Review in Eye (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Sugammadex and intraocular pressure: systematic review with meta-analysis and trial sequential analysis.BMC anesthesiology · 2026Pooled it
- Comparing combined laser iridoplasty and surgical iridectomy with trabeculectomy in treatment of refractory acute primary angle closure without significant cataract: a randomized controlled trial.Eye (London, England) · 2023Trial
- Microsphere-loaded dual-responseJournal of pharmaceutical analysis · 2026Article
- Systemic Medications as Triggers of Acute Angle-Closure Glaucoma: A Narrative Review.Journal of clinical medicine · 2026Review
- Seventeen-Year Clinical Analysis of Acute Primary Angle-Closure Glaucoma at a Single Japanese Tertiary Center.Cureus · 2026Article
- Levels of vascular endothelial growth factor and filtration surgery outcomes in diabetic patients with acute primary angle closure.Frontiers in medicine · 2026Article
- Mannitol plus pilocarpine for primary acute angle-closure glaucoma: efficacy and safety analysis.American journal of translational research · 2026Article
- Phacoemulsification combined with goniosynechialysis for acute angle-closure glaucoma: impact of preoperative IOP status.BMC ophthalmology · 2025Article
- Outcomes of laser peripheral iridotomy in subgroups of primary angle closure disease eyes according to swept-source optical coherence tomography parameters.Eye (London, England) · 2025Article
- ACM-Assessor: An Artificial Intelligence System for Assessing Angle Closure Mechanisms in Ultrasound Biomicroscopy.Bioengineering (Basel, Switzerland) · 2025Article
- Trabeculectomy versus stepwise treatment for breaking the attack of acute primary angle closure in patients with long attack duration: study design and protocol for a multicentre randomised controlled trial (LAAAC).BMJ open ophthalmology · 2025Article
- The change of retinal microvascular in APAC eyes and fellow PACS eyes detected using wide-field swept-source optical coherence tomographic angiography.Frontiers in medicine · 2025Article
- Swept-source optical coherence tomography assessment of Schlemm's canal after phacoemulsification with goniosynechialysis in Chinese patients with primary angle-closure glaucoma.Quantitative imaging in medicine and surgery · 2024Article
- Visually significant ocular decompression retinopathy following laser peripheral iridotomy in a patient with primary acute angle-closure glaucoma.American journal of ophthalmology case reports · 2024Article
- The profile of patients attending to the general emergency department with ocular complaints within the last year: is it a true ocular emergency?BMC ophthalmology · 2024Article
- Article
- The spike of acute angle closure after the epidemic downgrade of COVID-19 management: a hospital-based comparative study from China.International ophthalmology · 2024Article
- Low expression of TGF-β2 and matrilin2 in human aqueous humour with acute primary angle closure.Journal of cellular and molecular medicine · 2024Article
- Phacoemulsification versus Laser Peripheral Iridotomy for Treating Primary Angle Closure Glaucoma: A Systematic Review and Meta-Analysis.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- Three-dimensional choroidal vascularity index and choroidal thickness in fellow eyes of acute and chronic primary angle-closure using swept-source optical coherence tomography.International journal of ophthalmology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute primary angle closure requires emergency management that involves a rapid lowering of the intraocular pressure and resolution of relative pupil block - the most common mechanism of angle closure. Emergency strategies for lowering intraocular pressure include medical treatment and argon laser peripheral iridoplasty. Anterior chamber paracentesis and diode laser transcleral cyclophotocoagulation may be considered in special situations. Relative pupil block can be relieved by peripheral laser iridotomy and primary lens extraction; the latter is a more effective treatment according to the results of clinical trials. However, primary lens extraction can be technically demanding in the acute setting. Peripheral laser iridotomy has a role in relieving pupil block and should also be considered in most cases. Lens extraction may be combined with procedures such as goniosynechialysis, trabeculectomy or endoscopic cyclophotocoagulation. In this review, we aim to discuss the available evidence regarding the different treatment modalities. We also discuss the economic consideration, including cost-effectiveness and life expectancy, in the management of acute primary angle closure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.